News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
UK Suspends Novartis Corporation Drug Prexige on Liver Fears
November 19, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Nov 19 (Reuters) - Britain's Medicines and Healthcare products Regulatory Agency said on Monday it had suspended the licence on Novartis AG's painkiller Prexige due to safety concerns about possible liver damage.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
Opinion
US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe
June 16, 2025
·
6 min read
·
Craig Koch
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
May 13, 2025
·
5 min read
·
Angela Gabriel
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
·
2 min read
·
Tristan Manalac
